Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private PartnershipsCLINICAL CANCER RESEARCHIF10.22023-10-300OAAI
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400IJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTEIF7.22023-01-106PRE
Accelerating the development of innovative cellular therapy products for the treatment of cancerCYTOTHERAPYIF3.22020-05-018OAAI
Impact of breakthrough therapy designation on cancer drug developmentNATURE REVIEWS DRUG DISCOVERYIF101.82016-03-0234OA
Considerations for the successful co-development of targeted cancer therapies and companion diagnosticsNATURE REVIEWS DRUG DISCOVERYIF101.82013-09-0669PREAI
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval适应性许可: 迈出药物批准发展的下一步CLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52012-02-15202PREAI
Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In EuropeHEALTH AFFAIRSIF8.12011-07-0158PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向